Gemphire Therapeutics (NASDAQ:GEMP) Cut to “Sell” at ValuEngine

Gemphire Therapeutics (NASDAQ:GEMP) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, June 26th, ValuEngine reports.

Separately, Zacks Investment Research cut shares of Hersha Hospitality Trust from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the stock. Gemphire Therapeutics has a consensus rating of “Hold” and an average target price of $14.90.

Shares of GEMP stock traded up $0.02 during trading hours on Wednesday, hitting $0.73. The company’s stock had a trading volume of 26,016 shares, compared to its average volume of 185,077. The stock has a 50 day simple moving average of $0.84. Gemphire Therapeutics has a 12-month low of $0.57 and a 12-month high of $8.27. The stock has a market cap of $10.40 million, a PE ratio of -0.43 and a beta of 2.90.

Gemphire Therapeutics (NASDAQ:GEMP) last posted its earnings results on Thursday, May 9th. The company reported ($0.27) earnings per share (EPS) for the quarter.

Gemphire Therapeutics Company Profile

Gemphire Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy.

Read More: Trading Ex-Dividend Strategy

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gemphire Therapeutics (NASDAQ:GEMP)

Receive News & Ratings for Gemphire Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemphire Therapeutics and related companies with's FREE daily email newsletter.